Therapeutic targets in hypertension: Is there a place for antagonists of the most potent vasoconstrictors?

Fernanda R.C. Giachini, Glaucia E. Callera, Fernando S. Carneiro, Rita C. Tostes, R Clinton Webb

Research output: Contribution to journalReview article

14 Citations (Scopus)

Abstract

Background: Endothelin-1 (ET-1) and urotensin II (U-II) are the most potent and unusually long-lasting constrictors of human vessels known to date. Objective: In this review, we focus on the vascular effects of endothelin-1 (ET-1) and urotensin II (U-II) and their role in the pathophysiology of hypertension. Results and conclusion: Unlike ET-1, which uniformly constricts most blood vessels, the vasoactive effects of U-II depend both on the species, vascular bed and vessel calibre. Both ET-1 and U-II have potent mitogenic, pro-inflammatory and pro-oxidative properties, which have been implicated in the pathogenesis of human cardiovascular and renal diseases. The availability of highly effective peptide and non-peptide antagonists both for ET-1 and U-II receptors has revealed a role for these potent vasoconstrictor peptides in human (patho)physiology.

Original languageEnglish (US)
Pages (from-to)327-339
Number of pages13
JournalExpert Opinion on Therapeutic Targets
Volume12
Issue number3
DOIs
StatePublished - Mar 1 2008
Externally publishedYes

Fingerprint

Vasoconstrictor Agents
Endothelin-1
Hypertension
Blood Vessels
Therapeutics
Peptides
Physiology
Blood vessels
Cardiovascular Diseases
urotensin II
Availability
Kidney

Keywords

  • Endothelial cells
  • Endothelin-1
  • Hypertension
  • Urotensin II
  • Vascular smooth muscle cells

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry

Cite this

Therapeutic targets in hypertension : Is there a place for antagonists of the most potent vasoconstrictors? / Giachini, Fernanda R.C.; Callera, Glaucia E.; Carneiro, Fernando S.; Tostes, Rita C.; Webb, R Clinton.

In: Expert Opinion on Therapeutic Targets, Vol. 12, No. 3, 01.03.2008, p. 327-339.

Research output: Contribution to journalReview article

Giachini, Fernanda R.C. ; Callera, Glaucia E. ; Carneiro, Fernando S. ; Tostes, Rita C. ; Webb, R Clinton. / Therapeutic targets in hypertension : Is there a place for antagonists of the most potent vasoconstrictors?. In: Expert Opinion on Therapeutic Targets. 2008 ; Vol. 12, No. 3. pp. 327-339.
@article{6726b035a8a14924b3512f05c52dcf3e,
title = "Therapeutic targets in hypertension: Is there a place for antagonists of the most potent vasoconstrictors?",
abstract = "Background: Endothelin-1 (ET-1) and urotensin II (U-II) are the most potent and unusually long-lasting constrictors of human vessels known to date. Objective: In this review, we focus on the vascular effects of endothelin-1 (ET-1) and urotensin II (U-II) and their role in the pathophysiology of hypertension. Results and conclusion: Unlike ET-1, which uniformly constricts most blood vessels, the vasoactive effects of U-II depend both on the species, vascular bed and vessel calibre. Both ET-1 and U-II have potent mitogenic, pro-inflammatory and pro-oxidative properties, which have been implicated in the pathogenesis of human cardiovascular and renal diseases. The availability of highly effective peptide and non-peptide antagonists both for ET-1 and U-II receptors has revealed a role for these potent vasoconstrictor peptides in human (patho)physiology.",
keywords = "Endothelial cells, Endothelin-1, Hypertension, Urotensin II, Vascular smooth muscle cells",
author = "Giachini, {Fernanda R.C.} and Callera, {Glaucia E.} and Carneiro, {Fernando S.} and Tostes, {Rita C.} and Webb, {R Clinton}",
year = "2008",
month = "3",
day = "1",
doi = "10.1517/14728222.12.3.327",
language = "English (US)",
volume = "12",
pages = "327--339",
journal = "Expert Opinion on Therapeutic Targets",
issn = "1472-8222",
publisher = "Informa Healthcare",
number = "3",

}

TY - JOUR

T1 - Therapeutic targets in hypertension

T2 - Is there a place for antagonists of the most potent vasoconstrictors?

AU - Giachini, Fernanda R.C.

AU - Callera, Glaucia E.

AU - Carneiro, Fernando S.

AU - Tostes, Rita C.

AU - Webb, R Clinton

PY - 2008/3/1

Y1 - 2008/3/1

N2 - Background: Endothelin-1 (ET-1) and urotensin II (U-II) are the most potent and unusually long-lasting constrictors of human vessels known to date. Objective: In this review, we focus on the vascular effects of endothelin-1 (ET-1) and urotensin II (U-II) and their role in the pathophysiology of hypertension. Results and conclusion: Unlike ET-1, which uniformly constricts most blood vessels, the vasoactive effects of U-II depend both on the species, vascular bed and vessel calibre. Both ET-1 and U-II have potent mitogenic, pro-inflammatory and pro-oxidative properties, which have been implicated in the pathogenesis of human cardiovascular and renal diseases. The availability of highly effective peptide and non-peptide antagonists both for ET-1 and U-II receptors has revealed a role for these potent vasoconstrictor peptides in human (patho)physiology.

AB - Background: Endothelin-1 (ET-1) and urotensin II (U-II) are the most potent and unusually long-lasting constrictors of human vessels known to date. Objective: In this review, we focus on the vascular effects of endothelin-1 (ET-1) and urotensin II (U-II) and their role in the pathophysiology of hypertension. Results and conclusion: Unlike ET-1, which uniformly constricts most blood vessels, the vasoactive effects of U-II depend both on the species, vascular bed and vessel calibre. Both ET-1 and U-II have potent mitogenic, pro-inflammatory and pro-oxidative properties, which have been implicated in the pathogenesis of human cardiovascular and renal diseases. The availability of highly effective peptide and non-peptide antagonists both for ET-1 and U-II receptors has revealed a role for these potent vasoconstrictor peptides in human (patho)physiology.

KW - Endothelial cells

KW - Endothelin-1

KW - Hypertension

KW - Urotensin II

KW - Vascular smooth muscle cells

UR - http://www.scopus.com/inward/record.url?scp=41049104227&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=41049104227&partnerID=8YFLogxK

U2 - 10.1517/14728222.12.3.327

DO - 10.1517/14728222.12.3.327

M3 - Review article

C2 - 18269342

AN - SCOPUS:41049104227

VL - 12

SP - 327

EP - 339

JO - Expert Opinion on Therapeutic Targets

JF - Expert Opinion on Therapeutic Targets

SN - 1472-8222

IS - 3

ER -